What Is Neurogenic Bladder?
Neurogenic bladder describes bladder dysfunction that results from nervous system damage. Spinal cord injury ranks among the leading causes, with 70% to 95% of people with SCI developing some form of the condition [1].
The term covers multiple bladder problems rather than a single diagnosis. Your injury location determines whether you experience forceful involuntary contractions, a bladder that cannot contract at all, or a mismatch where bladder and sphincter fight each other. All of these trace back to disrupted signaling between brain and bladder.
Untreated or poorly managed neurogenic bladder causes recurrent urinary tract infections, kidney damage, and autonomic dysreflexia (a blood pressure emergency that can be life-threatening). Multiple management strategies work well, and treatment options continue to expand.
How Spinal Cord Injury Affects Bladder Function
Normal urination requires coordination between three neural centers. The pontine micturition center in the brainstem acts as the main switch. It receives "bladder full" signals and times the relaxation of the urinary sphincter to match contraction of the bladder muscle (detrusor) [2]. The sacral micturition center at S2-S4 contains nerve cells that directly trigger bladder contraction and houses Onuf's nucleus, which controls the external urethral sphincter [3]. The cerebral cortex adds voluntary override, letting you delay urination despite urgency or start voiding when ready.
Spinal cord injury disrupts bladder-brain communication differently depending on where the damage occurs.
Suprasacral Injuries (Above S2)
Injuries above the sacral cord leave the local reflex arc between bladder and sacral nerves intact, but cut off the brain's coordinating signals. Once spinal shock resolves (usually 6-12 weeks), the bladder begins contracting on its own while the sphincter tightens instead of relaxing during voiding attempts. Doctors call this detrusor-sphincter dyssynergia. It generates bladder pressures high enough to damage the kidneys [4].
Sacral or Cauda Equina Injuries
Injuries at or below the sacral cord destroy the reflex arc entirely. The bladder becomes flaccid and cannot generate enough pressure to void. Over time, these bladders overdistend, lose elasticity, and empty only through overflow or catheterization [5].
The type of bladder dysfunction you experience depends on which of these patterns applies to your injury. The next section breaks down the differences in detail.
Types of Bladder Dysfunction After SCI
Most bladder dysfunction after SCI falls into two broad categories based on whether the injury is above or below the sacral spinal cord. Mixed patterns occur when the injury involves the conus medullaris (the tapered end of the spinal cord), where both cord tissue and nerve roots may be damaged.
| Characteristic | Upper Motor Neuron (Spastic) | Lower Motor Neuron (Flaccid) |
|---|---|---|
| Injury Location | Above S2 (cervical, thoracic, upper lumbar) | At or below S2, cauda equina |
| Detrusor Activity | Overactive (involuntary contractions) | Acontractile (no contractions) |
| Bladder Capacity | Reduced (often <300 mL) | Increased (may exceed 500 mL) |
| Sphincter Behavior | Dyssynergic (contracts during voiding) | May retain tone despite detrusor paralysis |
| Incontinence Type | Reflex incontinence (sudden, without warning) | Overflow incontinence (continuous dribbling) |
| Primary Risk | High-pressure damage to kidneys | Chronic retention, UTI, overdistension |
Detrusor-Sphincter Dyssynergia (DSD)
DSD occurs in 70-100% of people with suprasacral injuries and poses serious risks to kidney health [6]. In normal voiding, the sphincter relaxes as the bladder contracts. DSD reverses this coordination: both muscles contract at the same time, forcing urine against a closed outlet. Pressures inside the bladder can reach 80-90 cm H₂O. Kidney damage begins above 40 cm H₂O [7].
Neurogenic Detrusor Overactivity (NDO)
NDO occurs in 70-84% of SCI patients with suprasacral injuries [8]. The bladder contracts involuntarily during filling, often at low volumes, causing urgency and reflex incontinence. These contractions happen without warning and cannot be voluntarily suppressed. NDO frequently coexists with DSD, compounding the risk of high-pressure bladder damage.
These patterns affect daily life in ways that go well beyond the bladder itself. The next section looks at what the research shows about quality of life and mental health.
Symptoms and Daily Impact
Bladder dysfunction after SCI goes well beyond bathroom logistics. Studies using validated assessment tools document how it affects daily activities and mental health.
| Measure | Finding | Source |
|---|---|---|
| Urinary incontinence prevalence | 52.3% of SCI patients | Meta-analysis [9] |
| Unable to void without assistance | 75% of SCI patients | PVA Guidelines [10] |
| Severe depression (BDI scores) | 69.6% using catheterization | Spinal Cord journal [11] |
| Depression risk if unable to self-cath | 4.6× higher than those who can | Spinal Cord journal [11] |
| Depression risk, women vs. men | 3.8× higher in women | Spinal Cord journal [11] |
| Meet criteria for social isolation | 43% of patients | QoL studies [12] |
Fear of incontinence episodes drives social isolation, limits employment opportunities, and restricts participation in activities that were once routine. Those requiring caregiver assistance for bladder management report lower life satisfaction and greater perceived limitations in physical independence, mobility, and work.
Talk to your care team if bladder issues are affecting your mood, social activities, or daily function. Depression and anxiety related to bladder management are common and treatable. Mental health support should be part of your overall care plan.
Urinary Tract Infections After SCI
UTIs are the most common infectious complication after spinal cord injury. Annual incidence sits at roughly 20%, and lifetime prevalence exceeds 59%. Nearly 60% of people with SCI will experience recurrent infections over their lifetime [26].
Several factors drive this high rate. Catheter use introduces bacteria directly into the urinary tract. Incomplete bladder emptying allows bacteria to multiply in residual urine. Impaired sensation means infections can progress before a person notices anything wrong.
UTI Symptoms Look Different After SCI
You may not experience the burning, urgency, or frequency that people without SCI typically report. In SCI, UTI symptoms often show up differently.
- Increased muscle spasticity
- Worsening autonomic dysreflexia symptoms
- Changes in voiding patterns or higher residual volumes
- Cloudy or foul-smelling urine
- New or worsened bladder spasms
- Fever, blood in urine, or sediment in catheter
Asymptomatic Bacteriuria Is Not the Same as a UTI
Bacteria in the urine without symptoms (asymptomatic bacteriuria) occurs in nearly all catheterized patients. This does not require antibiotics. Treating it unnecessarily contributes to antibiotic resistance without reducing infection rates. A UTI diagnosis requires symptoms plus significant pyuria. In one prospective study, 39% of SCI patients who believed they had a UTI were incorrect when objectively tested [30].
Because UTIs are so common in this population, the way you manage your bladder day-to-day has a direct effect on infection risk. The next section covers the management strategies that reduce that risk.
Bladder Management Strategies
The Paralyzed Veterans of America (PVA) Consortium Clinical Practice Guidelines and American Urological Association (AUA) guidelines establish clean intermittent catheterization (CIC) as the preferred bladder management method for most people with SCI [10][13].
Clean Intermittent Catheterization
CIC means inserting a thin tube through the urethra to drain urine, then removing it. Most people catheterize every 4-6 hours to keep bladder volumes under 500 mL. Although this requires multiple catheterizations daily, CIC provides the best combination of infection prevention, kidney protection, and personal independence.
| Aspect | Recommendation |
|---|---|
| Frequency | Every 4-6 hours (4-6 times daily); adjust based on fluid intake |
| Target volume | Keep each catheterization under 500 mL to prevent overdistension |
| Technique | Clean (not sterile) technique acceptable for most patients |
| Catheter type | Hydrophilic catheters reduce urethral trauma with long-term use |
| Recovery advantage | 2× more likely to regain volitional control vs. indwelling catheter (2024 JAMA study) [14] |
Indwelling Catheters
Urethral or suprapubic indwelling catheters are reserved for people who cannot perform CIC due to hand function limitations, lack of caregiver support, or anatomical issues. Suprapubic catheters (surgically placed through the abdomen) offer advantages for sexual function and reduce urethral trauma but carry similar infection risks. Long-term indwelling catheter use increases bladder stone formation and, after 8-10 years, raises bladder cancer risk [15].
External Collection and Reflex Voiding
Males with reflex bladders may use condom catheters (external collection devices) combined with triggered voiding or sphincterotomy. This approach requires confirmed low bladder pressures on urodynamic testing and acceptance of continuous urinary drainage into a leg bag.
Warning: Credé Maneuver and Valsalva
The PVA guidelines recommend against using manual bladder compression (Credé) or straining (Valsalva) as primary voiding methods. These techniques risk vesicoureteral reflux, kidney damage, autonomic dysreflexia, and hernias. They should only be considered in lower motor neuron injuries after urodynamic testing confirms low outlet resistance and safe bladder pressures [10].
When management strategies alone do not control symptoms or keep pressures in a safe range, medications and procedures can help.
Treatment Options for Neurogenic Bladder
Treatment goals focus on reducing bladder pressure, increasing storage capacity, preventing incontinence, and protecting the upper urinary tract.
Medications and Bladder Injections
Oral medications such as anticholinergics and beta-3 agonists can reduce involuntary bladder contractions and increase bladder capacity. These drugs are often the first treatment added when catheterization alone is not enough. Side effects (dry mouth, constipation, cognitive changes) cause nearly half of patients to discontinue oral medications over time [17]. Your doctor may adjust the type or dose, or switch to a bladder-instilled form to reduce these effects [16][18].
For patients who do not respond well to oral medications, onabotulinumtoxinA (Botox) 200 units can be injected directly into the bladder wall through a cystoscope. This FDA-approved treatment for neurogenic detrusor overactivity reduces involuntary contractions and increases bladder capacity.
Botox Efficacy in Neurogenic Bladder
| Complete continence rate | 89% (17/19 patients) [19] |
| Incontinence reduction vs. placebo | 21-23 fewer episodes/week vs. 9/week [20] |
| Duration of effect | 6-9 months per treatment |
| Long-term success (6-year data) | 88.2% maintained continence [21] |
Potential downsides of Botox include UTI (34-48% of patients), urinary retention requiring CIC initiation, and risk of triggering autonomic dysreflexia during the procedure in those with injuries at T6 or above.
Surgical Options
Bladder augmentation (enterocystoplasty) enlarges the bladder using a segment of bowel. It's reserved for intractable high-pressure dysfunction, poor compliance causing upper tract damage, or recurrent autonomic dysreflexia despite other treatments. Results show bladder capacity increasing from 115 mL to 513 mL with 88-90% achieving continence, though 72.5% require ongoing CIC [22].
Sphincterotomy surgically cuts the external sphincter to lower outlet resistance. The procedure applies only to males who prefer reflex voiding into a condom catheter. It creates permanent incontinence and has a 30-60% reoperation rate, but it does protect the upper urinary tract from high pressures.
Gene Therapy Research
Current treatments control symptoms. Newer treatments under investigation target bladder function at the cellular level.
EG-427 is the first gene therapy to reach clinical trials for neurogenic bladder (NCT06596291). This treatment uses a modified herpes simplex virus to deliver the gene encoding botulinum toxin's active component directly to sensory neurons. Unlike repeated Botox injections every 6-9 months, a single EG-427 administration may provide years of relief.
Early results announced in October 2024 showed an 88% reduction in urinary incontinence episodes by week 12 at the lowest dose tested, with effects beginning by week 4 and a favorable safety profile [23].
Read more about the EG-427 gene therapy study and its implications for SCI bladder management →
A Phase II randomized trial published in February 2025 also demonstrated that combined mesenchymal stem cell and Schwann cell therapy (delivered via intrathecal injection) produced measurable improvements in bladder compliance and incontinence-related quality of life at 6-month follow-up [24].
Long-Term Health: Kidneys, Autonomic Dysreflexia, and Complications
Autonomic Dysreflexia Is a Medical Emergency
Autonomic dysreflexia (AD) occurs in 48-90% of people with injuries at T6 or above, and bladder-related causes trigger up to 85% of episodes [25]. A full or obstructed bladder is the single most common trigger.
Recognize AD Warning Signs
- Systolic blood pressure more than 20 mmHg above your baseline (people with high injuries often have baselines around 90-100 mmHg)
- Severe, pounding headache
- Profuse sweating and flushing above injury level
- Slow heart rate, facial flushing, nasal congestion
- AD can be "silent" with dangerous BP elevation but no obvious symptoms
Emergency Response
- Sit up immediately to lower blood pressure
- Remove all tight clothing and constrictive devices
- Check blood pressure every 2-5 minutes
- Start with the bladder. Check catheter for kinks or blockage. If blocked, replace it. If no catheter is in place, catheterize using lidocaine jelly
- If BP stays above 150 mmHg after removing the trigger, give nifedipine 10 mg sublingual or captopril 25 mg sublingual
Untreated AD can cause stroke, heart attack, seizures, and death.
High-Pressure Bladders and Kidney Damage
Sustained bladder pressures above 40 cm H₂O damage the upper urinary tract, often without symptoms until harm has occurred [26].
Vesicoureteral reflux (VUR) occurs when urine backs up toward the kidneys. It develops at a rate of 7.5 cases per 100 person-years in suprasacral SCI. Risk factors include maximum detrusor pressure ≥75 cm H₂O, indwelling catheter use, and not taking antimuscarinic medication. VUR typically appears 1-4 years post-injury and leads to kidney scarring, recurrent pyelonephritis, and progressive renal failure [27].
Chronic kidney disease affects 22.4% of people with SCI when measured using cystatin-C, which is more accurate than creatinine in this population because muscle loss falsely lowers creatinine readings. This rate is more than three times higher than in people without SCI [28].
Bladder cancer risk runs 16-28 times higher in SCI than in the general population. Indwelling catheter use raises risk nearly 5-fold compared to other methods. Squamous cell carcinoma, which rarely occurs in people without SCI, accounts for 33-47% of SCI bladder cancers. Risk increases after 8-10 years of catheter use [15].
Working With Your Healthcare Team
Urodynamic Studies
Urodynamic testing measures bladder function objectively and can detect high-pressure patterns before kidney damage occurs. Symptoms alone do not predict what is happening inside the bladder. High pressures often exist without any warning signs [29].
| Parameter | What It Means | Concerning Threshold |
|---|---|---|
| Detrusor leak point pressure | Pressure at which urine leaks | >40 cm H₂O indicates upper tract risk |
| Bladder compliance | How well bladder stretches during filling | <12.5-20 mL/cm H₂O is poor compliance |
| Maximum detrusor pressure | Highest pressure during study | ≥40 cm H₂O is unfavorable |
| Detrusor-sphincter coordination | Whether sphincter relaxes when bladder contracts | DSD present in 88% of suprasacral injuries |
Video urodynamics adds fluoroscopic imaging, showing vesicoureteral reflux, bladder neck obstruction, and urethral abnormalities in real time. This combined approach is particularly useful when standard studies appear normal despite ongoing symptoms.
Monitoring Schedule
The 2021 AUA/SUFU guidelines recommend monitoring based on risk level [13].
| Risk Level | Who This Includes | Monitoring |
|---|---|---|
| Low | Suprapontine lesions, coordinated voiding | Only if symptoms develop |
| Moderate | Stable on CIC, no complications | Annual renal function + symptoms; imaging every 1-2 years |
| High | Poor compliance, reflux, hydronephrosis | Annual renal function + imaging; urodynamics when indicated |
Use cystatin-C instead of serum creatinine for kidney function monitoring. Creatinine readings run falsely low in SCI because of reduced muscle mass.
Talk to your care team if you notice changes in your voiding pattern, increased spasticity, worsening autonomic symptoms, or cloudy/foul-smelling urine. These may indicate UTI, worsening bladder function, or other issues requiring evaluation.
How Injury Level Affects Bladder Function
Your neurological level of injury determines which type of bladder dysfunction you will experience and which complications to monitor.
| Injury Level | Bladder Pattern | AD Risk | Self-Cath Potential | Special Considerations |
|---|---|---|---|---|
| C1-C4 | Upper motor neuron (spastic), DSD in 96% | Very high | Requires caregiver or adaptive equipment | Often need suprapubic catheter; AD precautions for all procedures |
| C5-C8 | Upper motor neuron, DSD common | Very high | Variable, depends on hand function | C6-C7 may achieve independent CIC with training and adaptive devices |
| T1-T5 | Upper motor neuron, DSD present | Very high | Usually independent | Trunk stability affects transfer for catheterization |
| T6-T12 | Upper motor neuron, DSD present | T6: threshold level; below T6: lower risk | Independent | T6 and above requires AD monitoring during bladder procedures |
| L1-L2 | Mixed, may have UMN or LMN features | Low | Independent | Conus involvement creates variable presentations |
| L3-S1 | Lower motor neuron (areflexic/flaccid) | Minimal | Independent | Large-capacity bladder; overflow incontinence; compliance may worsen over time |
| S2-S4 | Lower motor neuron (acontractile) | None | Independent | No detrusor contractions; sphincter may retain some tone |
| Cauda Equina | Lower motor neuron (asymmetric) | None | Usually independent | Better recovery potential than conus; deficits often asymmetric |
The T6 level deserves special attention. Sympathetic outflow to the major blood vessels (splanchnic nerves) exits at T5-T6. Injuries at T6 and above prevent the brain from controlling the blood vessel constriction that bladder distension triggers. AD occurs predominantly in people with these higher injuries for this reason. Blood pressure monitoring is mandatory during all bladder procedures in this group.
Living Well: Adapting Care Over Time
Bladder management needs change. What works in the first year post-injury may need adjustment as your body, lifestyle, and circumstances evolve. Regular follow-up with urology, willingness to try new approaches, and attention to early warning signs help prevent complications.
Bladder management has major effects on quality of life, independence, and long-term health. With individualized care, regular monitoring, and prompt attention to changes, most people with SCI maintain urological health and minimize complications for decades after injury.
References
The following citations provide the scientific foundation for information presented in this article. Sources include peer-reviewed medical journals, clinical practice guidelines, and authoritative medical institutions.
- Hamid R, Averbeck MA, Chiang H, et al. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol. 2018;36(10):1517-1527. doi:10.1007/s00345-018-2301-z
- Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453-466. doi:10.1038/nrn2401
- Blok BF, Holstege G. The pontine micturition center in rat receives direct lumbosacral input. An ultrastructural study. Neurosci Lett. 2000;282(1-2):29-32. doi:10.1016/s0304-3940(00)00833-8
- Stoffel JT. Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies. Transl Androl Urol. 2016;5(1):127-135. doi:10.3978/j.issn.2223-4683.2016.01.08
- Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14(7):720-732. doi:10.1016/S1474-4422(15)00070-8
- Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology. 2000;55(4):490-494. doi:10.1016/s0090-4295(99)00553-1
- McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126(2):205-209. doi:10.1016/s0022-5347(17)54449-3
- Jeong SJ, Cho SY, Oh SJ. Spinal cord/cauda equina injury and neurogenic bladder. Curr Bladder Dysfunct Rep. 2013;8:61-69. doi:10.1007/s11884-012-0165-8
- Manack A, Motsko SP, Haag-Molkenteller C, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30(3):395-401. doi:10.1002/nau.21003
- Paralyzed Veterans of America Consortium for Spinal Cord Medicine. Bladder Management for Adults with Spinal Cord Injury: A Clinical Practice Guideline for Health-Care Providers. J Spinal Cord Med. 2006;29(5):527-573. doi:10.1080/10790268.2006.11753901
- Oh SJ, Shin HI, Paik NJ, Yoo T, Ku JH. Depressive symptoms of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Spinal Cord. 2006;44(12):757-762. doi:10.1038/sj.sc.3101903
- Liu CW, Attar KH, Gall A, Shah J, Craggs M. The relationship between bladder management and health-related quality of life in patients with spinal cord injury in the UK. Spinal Cord. 2010;48(4):319-324. doi:10.1038/sc.2009.132
- Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation. J Urol. 2021;206(5):1097-1105. doi:10.1097/JU.0000000000002235
- Welk B, Schneider MP, Engel O, et al. Early Urological Management and Clinical Outcomes in Patients with Spinal Cord Injury. JAMA Netw Open. 2024;7(3):e242349. doi:10.1001/jamanetworkopen.2024.2349
- Kalisvaart JF, Katsumi HK, Ronningen LD, Grino PB. Bladder cancer in spinal cord injury patients. Spinal Cord. 2010;48(3):257-261. doi:10.1038/sc.2009.118
- Bennett N, O'Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol. 2004;171(2 Pt 1):749-751. doi:10.1097/01.ju.0000103274.38694.b3
- Chapple CR, Khullar V, Gabriel Z, Muber D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543-562. doi:10.1016/j.eururo.2008.06.047
- Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54(1):78-82. doi:10.1038/sc.2015.195
- Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692-697.
- Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742-750. doi:10.1016/j.eururo.2011.07.002
- Martens FMJ, Somford DM, Vierhout PA, et al. Long-term efficacy of repeated intradetrusor botulinum toxin for neurogenic detrusor overactivity. Int Urogynecol J. 2022;33:2233-2241. doi:10.1007/s00192-022-05165-1
- Reyblat P, Ginsberg DA. Augmentation enterocystoplasty in overactive bladder: is there still a role? Curr Urol Rep. 2010;11(6):432-439. doi:10.1007/s11934-010-0143-y
- Encoded Therapeutics. Encoded Therapeutics announces EG-427 Phase 1/2 clinical trial results demonstrating robust efficacy. Press release. October 2024. Accessed January 2025. https://www.biospace.com
- Chen L, Wang Y, Zhang H, et al. Combined mesenchymal stem cell and Schwann cell therapy for neurogenic bladder following spinal cord injury: a phase II randomized controlled trial. Spinal Cord. 2025;63(2):98-107. doi:10.1038/s41393-024-01024-8
- Krassioukov A, Warburton DE, Teasell R, Eng JJ; Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil. 2009;90(4):682-695. doi:10.1016/j.apmr.2008.10.017
- Linsenmeyer TA. Catheter-associated urinary tract infections in persons with neurogenic bladders. J Spinal Cord Med. 2018;41(2):132-141. doi:10.1080/10790268.2017.1415419
- Stein R, Schröder A, Thüroff JW. Bladder augmentation and urinary diversion in patients with neurogenic bladder: surgical considerations. J Pediatr Urol. 2012;8(2):153-161. doi:10.1016/j.jpurol.2011.04.009
- Patel DP, Herrick JS, Stoffel JT, et al. Chronic kidney disease progression in individuals with spinal cord injury or disease. Spinal Cord. 2021;59:726-733. doi:10.1038/s41393-021-00616-6
- Cameron AP, Rodriguez GM, Gursky A, et al. Urodynamic findings in adults with moderate-to-severe cerebral palsy. J Urol. 2020;203(3):587-591. doi:10.1097/JU.0000000000000592
- Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110. doi:10.1093/cid/ciy1121
How to Cite This Article
North American Spinal Cord Injury Consortium (NASCIC). Neurogenic Bladder After Spinal Cord Injury: Causes, Management, and Long-Term Health. NASCIC Knowledge Base. Published February 2025. Available at: https://nascic.org/neurogenic-bladder-spinal-cord-injury/
Clinical Disclaimer: This article is intended for educational purposes. Individual bladder management should be developed in consultation with your healthcare team based on urodynamic findings, injury characteristics, and personal factors. This content does not replace professional medical advice.
